PsychoGenics Inc. is a preclinical contract research organization (CRO) based in Paramus, New Jersey. The company describes itself as "a preclinical CRO with expertise in CNS and orphan disorders"[S1] and lists its capabilities as "behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis."[S1] This profile summarizes the services, platforms, disease models, and stated compliance information that are most relevant to US drug developers evaluating a CNS-focused nonclinical partner.
Nonclinical services relevant to US drug developers
In vivo CNS pharmacology and behavioral testing
The company's service pages present in vivo work built around behavioral assays in mice and rats, with in-house support functions that it says let a sponsor "keep your project under one roof."[S3] Named service lines include single- or dual-probe microdialysis with in-house bioanalytical support,[S3] biomarker analysis,[S3] ex vivo sample analysis for target engagement,[S3] pharmacokinetic and pharmacodynamic (PK/PD) assessment that combines "in vivo dosing and tissue sampling" with analytical platforms to relate drug exposure to behavioral and biomarker readouts,[S3] and electrophysiology for customized study designs.[S3] The website lists eight therapeutic areas: epilepsy and seizure disorders (EEG and behavioral identification of seizures), mental illness, neurodegenerative disorders, neurodevelopmental disorders, neuromuscular disorders, pain, rare CNS disorders, and traumatic brain and spinal cord injury.[S5]
AI-enabled phenotypic screening platforms
PsychoGenics states that "in 2002, PsychoGenics embarked on a journey to apply automation and AI to drug discovery based on mouse behavior."[S4] Four proprietary platforms are described. SmartCube? is "an automated, high-throughput testing platform that employs machine learning" to extract behavioral signatures of test compounds in mice.[S4] NeuroCube? "detects and evaluates changes in gait" to assess treatments for motor impairment and pain in rats and mice.[S4] In PhenoCube?, mice "are observed continuously, day and night," so that social, circadian, motor, and cognitive behaviors can be tracked over time.[S4] eCube is described as a pharmaco-EEG platform that compares a compound's EEG signature against a database of marketed drugs.[S4] The company positions these tools for phenotypic drug discovery, which it defines as identifying treatments "based on their ability to rescue a disease phenotype in a cell or organism."[S4] Sponsors should treat platform outputs as nonclinical screening and profiling data; a behavioral or EEG signature in rodents does not by itself establish efficacy in patients, and the translational value of any signature has to be assessed program by program.
Disease models
The homepage lists "validated mouse models including in-licensed transgenic models" for Alzheimer's disease, Huntington's disease, Parkinson's disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy, and pain.[S1] Resource pages give examples: autism spectrum disorder models (Shank3, Cntnap2 knockout, and Fmr1 knockout mice),[S8] a Tsc2 knockout mouse model of tuberous sclerosis complex,[S9] and functional, sensorimotor, and cognitive outcome measures after unilateral middle cerebral artery occlusion (MCAO) in rats.[S10] Availability and licensing terms for in-licensed transgenic lines should be confirmed with the company for each study.
Quality, compliance, and animal welfare (as stated by the company)
GLP. The pages reviewed for this profile (home, about, services, therapeutic areas, platforms, corporate citizenship, and contact; accessed September 3, 2026) do not state that PsychoGenics conducts studies under Good Laboratory Practice (GLP) regulations and do not name 21 CFR Part 58 or any other GLP regulation. The reviewed service and platform pages describe pharmacology, profiling and biomarker work[S1][S3][S4]. Sponsors who need a GLP study, for example a nonclinical safety study intended to support an IND, should ask the company directly whether it conducts GLP studies and, if so, under which regulation and with what quality assurance unit; GLP compliance applies to individual nonclinical laboratory studies rather than to a company as a whole.[R2]
Accreditation and animal welfare. The company refers to "our AAALAC-accredited facility"[S2] and states that it "proudly maintains AAALAC accreditation and upholds the 3Rs principles," listing "Replacement of animals with non-animal methods where possible," "Reduction in the number of animals used," and "Refinement of procedures to prioritize animal welfare."[S6] No accreditation date, USDA registration, OLAW Animal Welfare Assurance, or IACUC statement was found on the pages reviewed. AAALAC International accreditation is a voluntary evaluation of an institution's animal care and use program, re-evaluated every three years,[R3] and USDA registration and an OLAW Animal Welfare Assurance relate to the Animal Welfare Act and the PHS Policy respectively;[R4][R5] none of these establishes GLP compliance, which applies to individual studies.[R2] FDA does not approve or certify laboratories; registration with FDA does not denote approval.[R6] This profile does not evaluate the company's animal care program; the statements above are the company's own.
215 College Road, Paramus, NJ 07652, United States[S7]
Ownership
Not stated on the company website (no parent company or stock listing is shown)[S2]
History
The company states that it began applying automation and AI to drug discovery based on mouse behavior in 2002; a founding year is not stated on the website[S4]
Sites
Paramus, New Jersey (the only site named on the website)[S7]
FDA ? "Is It Really FDA Approved?" (FDA does not approve health care providers, including laboratories; registration does not denote approval); FDA Compliance Program 7348.808 (GLP inspections of nonclinical laboratories). https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved (accessed 2026-09-03)
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.
Pharmacology (Efficacy) Studies Replicate unknown pathological models and Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
SMC Laboratories, Inc. has established a disease models using patented mouse technologies.
The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project.
Their collaborative approach allows researchers to discuss and refine study plans together with SMC’s expert scientists.
With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc. (Labcorp Drug Development)
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements.
All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials.
For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
PhoenixBio Co., Ltd. offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to–drug interaction studies, bridging the gap between preclinical and clinical stages.
With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides a seamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.
The company offers an integrated evaluation analysis covering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics.
For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.
Japanese
